72 results about "Reproductive technology" patented technology

The present invention relates to the use of an oxytocin receptor antagonist in females undergoing embryo transfer as part of an assisted reproductive technology. In particular, methods are provided for increasing ongoing implantation rate, increasing ongoing pregnancy rate, increasing clinical pregnancy rate, and / or increasing live birth rate in a female subject undergoing embryo transfer. Specifically, the antagonists are released in the luteal phase when the endometrium is receptive for embryo implantation and / or when the embryo has reached the blastocyst-stage.

Artificial insemination of female animals and in vitro fertilization of oocytes with fresh or frozen-thawed semen have been applied to the reproduction of animals. According to the traditional theory and conventional procedures, a great number of sperm cells are needed to ensure a successful fertilization.

Disclosed is a system for determining fecundity of an embryo utilizing a non¬ invasive grading of early stage embryos (pre-hatching) based upon specific gravity, density and / or estimated weight. The system allows 100% recovery of embryos and can detect differences in growth potential at the earliest stages of development. The system may further enhance the development of embryos by utilization of microfluidic effects during use. The disclosed system supports a wide variety of scenarios for human and animal reproductive technologies and related products and services.

The invention discloses in vitro human sperm culture solution for improving sperm motility and application thereof. The culture solution contains fructose 6-phosphoric acid (F6P). The in vitro human sperm culture solution for improving the sperm motility of human sperms is used for culturing the purified human sperms which leave from a human body; the vitality of normal human sperms is capable of maintaining sperm movement and can be obviously improved; and a meaningful reference is provided for improving and assisting the reproductive technology. The F6P is directly used for cultivating and diluting the culture solution, and does not relate to organic solvents such as ethanol or dimethylsulfoxide (DMSO) and the like; the toxic action of the ethanol or the DMSO on the sperms is avoided; by adopting the F6P added to the sperm culture solution, the vitality of the sperms of clinical patients with asthenospermia can be obviously improved; the improvement degree of the vitality is the most obvious for severe oligospermia; the activity of a part of cultured sperms reaches the normal sperm vitality range; and the improvement degree of the vitality for the severe oligospermia is the most obvious. This fully demonstrates that low motility of the sperms of the patients with asthenospermia can be improved by using of the F6P.

A method for qualitatively assessing products used in in vitro fertilization is provided. Also disclosed is an improved quality control assay for use in clinical Assisted Reproductive Technologies (ART).